Dear Mums, - and also Dads and single folk,
Reading the the paragraph below, RAP would not be expecting revenue from the hospital group for around 18 months? Yes, it provides both with valuable data but $ no....So assuming a successful BreatheEasy and SmartCough2 and successful FDA application, (I imagine) a similar LOI would be offered to other hospital groups, clinicians, doctors, etc..... with a similar time frame for evaluation.
Therefore, RAP would not be looking for meaningful revenue until at least July 2020 from any source?
This does not take into account any LOI for sleep apnea or other algorithms they produce.
I am thinking aloud and welcome all constructive comments. Completing trials successfully is one of the many small steps RAP need to finalise. Marketing and acquiring medical professionals to purchase the app is the next step. Building industry and community knowledge and confidence is another. Yes, share price appreciation will happen with successful trials and FDA/CE/? approvals but sustained growth (true value and further share price growth) requires $ coming in.
Please share your thoughts both +ve and -ve on this forum to help get a balanced view on where and when RAP is headed.
Kind regards,
Raindear
PS - first purchased Oct 2016 - LT here
Brisbane, Australia, 24 April 2018 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has signed a letter of intent (LOI) with a German private hospital network to run a pilot project to test the applicability and integration of ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease, within a German hospital structure. The partners will work together to design and run a six-month pilot project at one or more of the network’s hospitals in Germany at no-cost to ResApp. The pilot project must be started by November 1, 2018 and ResApp will not receive revenue from the pilot. At the completion of the project ResApp has agreed to grant the network an exclusive, no-cost license to use ResAppDx in their hospitals in Germany for six months and a non-exclusive, no-cost license for an additional six months. Successful completion of the pilot may lead to the network negotiating a commercial licensing agreement for use in their hospitals. Under the LOI neither party has taken on any obligations regarding ResAppDx following the pilot project and subsequent no-cost license periods. “We are excited to be working with a leading German hospital network. This gives us a unique opportunity to work closely with European clinicians and hospital executives, providing us with invaluable insight into European clinical practice and hospital operations,” said Tony Keating, CEO and Managing Director of ResApp Health. “We expect this project to significantly accelerate the commercialisation of ResAppDx in Europe.”
Expand